Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Economic Evaluation of New Drugs Important: Dr Matsutani of HPB
September 26, 2005
- Discount Rates for Catheters, Pacemakers Average 17%: Survey
September 26, 2005
- Staff Members Must Be Increased at ELD and PMDA: New PFSB Director General
September 26, 2005
- MEDICAL DEVICE NEWS IN BRIEF
September 26, 2005
- Meeting of CDFS's Department on Drugs
September 26, 2005
- NEW PRODUCTS
September 26, 2005
- JMA's Involvement in Recommendation of Reps. of Hosp. Org. Necessary: Korosho
September 26, 2005
- MARKET SURVEY
September 26, 2005
- REGULATORY NEWS IN BRIEF
September 26, 2005
- GENERICS NEWS IN BRIEF
September 26, 2005
- JPLA LECTURE
September 26, 2005
- Innovative Drugs Should Be Valued More Highly: Mr Otsuji
September 26, 2005
- Taisho Toyama Aims at \120 Mil. Sales per MR ASAP: Mr Uehara of Taisho
September 26, 2005
- Mr Fujii, New President of QTJ, Introduced by Dr Gillings
September 26, 2005
- Alfresa HD, Meisyo to Merge in April 2006
September 26, 2005
- BUSINESS NEWS IN BRIEF
September 26, 2005
- Goodrug to Begin Internet Sale of Generics on Oct. 1
September 19, 2005
- Incidence of Abnormality Rose in All Age Brackets in 2004: Health Examinations
September 19, 2005
- Kyorin to Back Up Toyo Pharmar in Earnest
September 19, 2005
- Kenporen Calls For Reductions in Medical Fees
September 19, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…